drugset / Trial / NCT03033069
A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)
Phase 2
Completed
336 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
H. Lundbeck A/S · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety, efficacy and tolerability of brexpiprazole (with placebo) as monotherapy or combination therapy with Zoloft (sertraline) in adults with PTSD.
Timeline
- Start
- 2017-01-26
- Primary completion
- 2018-11-12
- Completion
- 2018-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brexpiprazole | Small molecule | 1 mg | Oral |
| Subject | Brexpiprazole | Small molecule | 3 mg | Oral |
| Subject | Sertraline | Small molecule | 100 mg | Oral |
| Subject | Sertraline | Small molecule | 200 mg | Oral |